期刊
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 76, 期 2, 页码 385-395出版社
OXFORD UNIV PRESS
DOI: 10.1093/jac/dkaa447
关键词
-
资金
- Shelby Foundation
- National Cancer Institute [P30-CA016672]
- Cancer Prevention and Research Institute of Texas [RP150596]
- UT Southwestern
- NIAID [1K01AI143881-01]
- NIH/NIAID [K24AI121296, R01AI134637, R01AI148342-01, R21AI143229, P01AI152999-01]
- UTHealth Presidential Award
- University of Texas System STARS Award
- Texas Medical Center Health Policy Institute Funding Program
By analyzing genomic data and conducting serial passaging experiments on clinical ESBL-E isolates, this study revealed the IS26-mediated mechanisms of beta-lactamase gene amplification and outer membrane porin disruption driving the emergence of clinical non-CP-CRE. These amplifications were found to be stable in the absence of antimicrobial pressure, demonstrating the potential of long-read sequencing in identifying mobile genetic element mechanisms that contribute to antimicrobial resistance.
Background: Approximately half of clinical carbapenem-resistant Enterobacterales (CRE) isolates lack carbapenem-hydrolysing enzymes and develop carbapenem resistance through alternative mechanisms. Objectives: To elucidate development of carbapenem resistance mechanisms from clonal, recurrent ESBL-positive Enterobacterales (ESBL-E) bacteraemia isolates in a vulnerable patient population. Methods: This study investigated a cohort of ESBL-E bacteraemia cases in Houston, TX, USA. Oxford Nanopore Technologies long-read and Illumina short-read sequencing data were used for comparative genomic analysis. Serial passaging experiments were performed on a set of clinical ST131 Escherichia coli isolates to recapitulate in vivo observations. Quantitative PCR (q PCR) and qRT-PCR were used to determine copy number and transcript levels of beta-lactamase genes, respectively. Results: Non-carbapenemase-producing CRE (non-CP-CRE) clinical isolates emerged from an ESBL-E background through a concurrence of primarily IS26-mediated amplifications of bla(OXA-1) and bla(CTX-M-1) group genes coupled with porin inactivation. The discrete, modular translocatable units (TUs) that carried and amplified beta-lactamase genes mobilized intracellularly from a chromosomal, IS26-bound transposon and inserted within porin genes, thereby increasing beta-lactamase gene copy number and inactivating porins concurrently. The carbapenem resistance phenotype and TU-mediated beta-lactamase gene amplification were recapitulated by passaging a clinical ESBL-E isolate in the presence of ertapenem. Clinical non-CP-CRE isolates had stable carbapenem resistance phenotypes in the absence of ertapenem exposure. Conclusions: These data demonstrate IS26-mediated mechanisms underlying beta-lactamase gene amplification with concurrent outer membrane porin disruption driving emergence of clinical non-CP-CRE. Furthermore, these amplifications were stable in the absence of antimicrobial pressure. Long-read sequencing can be utilized to identify unique mobile genetic element mechanisms that drive antimicrobial resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据